P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance

Y. Xu; Z. Huang; Y. Fan

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance

【24h】

P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance

机译：P3.03-031在C-MET过表达NSCLC中发生响应CRizotinib，无论在第一线EGFR-TKI电阻后，都可以发生在C-MET过表达NSCLC中。

获取原文

获取原文并翻译 | 示例

获取外文期刊封面目录资料

开具论文收录证明 >>

文献代查 >>

文献数据库（团队版） >>

页面导航

著录项
引文网络
相似文献
相关主题

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2017年第11期|共2页
作者
Y. Xu; Z. Huang; Y. Fan;
展开▼
作者单位

Chemotherapy Zhejiang Cancer Hospital;

Chemotherapy Zhejiang Cancer Hospital;

Chemotherapy Zhejiang Cancer Hospital;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词

相似文献

外文文献
中文文献
专利

1. P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance [J] . Y. Xu, Z. Huang, Y. Fan Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2017,第11期

机译：P3.03-031在C-MET过表达NSCLC中发生响应CRizotinib，无论在第一线EGFR-TKI电阻后，都可以发生在C-MET过表达NSCLC中。
2. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance [J] . Xu Yanjun, Fan Yun Cancer biology & therapy . 2019,第1a3期

机译：在开发EGFR-TKI抗性后，在C-MET过表达NONSMALL细胞肺癌中可能发生对CRIZOTINIB的反应
3. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance [J] . Xu Yanjun, Fan Yun Nature reviews neuroscience . 2019,第2期

机译：在开发EGFR-TKI抗性后，在C-MET过表达的非粘附性肺癌中可以发生对蠕动in的反应
4. Responses to crizotinib can occur in c-MET overexpressing nonsmall cell lung cancer after developing EGFR-TKI resistance [O] . Yanjun Xu, Yun Fan 2019

机译：对克唑替尼的反应可能发生在表达EGFR-TKI耐药的过表达c-MET的非小细胞肺癌中
5. Lung adenocarcinoma harboring concomitant K fusion, c-Met overexpression, and amplification with inherent resistance to crizotinib, chemotherapy, and radiotherapy [O] . 2016

机译：肺腺癌伴有K融合，c-Met过表达和扩增，对克唑替尼，化学疗法和放射疗法有固有抵抗力

P3.03-031 Response to Crizotinib Can Occur in C-MET Overexpression NSCLC Independent of MET exon14 Alterations After First-Line EGFR-TKI Resistance

著录项

引文网络

相似文献

相关主题

期刊订阅